02532nam a22002897a 4500008004200000022001400042024003500056040002000091245009900111251006800210252005200278253011500330260000900445260001100454266001500465520019900480520058100679520017501260520054501435546001201980650003401992651003902026656003902065657002002104700002502124856009302149180818s20182018 xxu||||| |||| 00| 0 eng d a1526-6028 a10.1177/1526602818794030 [doi] aOvid MEDLINE(R) aPreoperative Use of Statins in Carotid Artery Stenting: A Systematic Review and Meta-analysis. aJournal of Endovascular Therapy. :1526602818794030, 2018 Aug 13 aJ Endovasc Ther. :1526602818794030, 2018 Aug 13 aJournal of endovascular therapy : an official journal of the International Society of Endovascular Specialists c2018 fFY2019 d2018-08-16 aCONCLUSION: Statin therapy prior to CAS is associated with decreased risk of perioperative stroke and death without any effect on the rates of transient ischemic attack or myocardial infarction. aMETHODS: All randomized and observational English-language studies of periprocedural statin administration prior to CAS that reported the outcomes of interest (stroke, transient ischemic attack, myocardial infarction, and death at 30 days) were included in a random-effects meta-analysis. The I2 statistic was used to assess heterogeneity. Meta-regression analysis was performed to determine whether an association of statin treatment with risk of outcome events was influenced by other trial-level baseline characteristics of statin-treated and untreated patients. aPURPOSE: To determine through meta-analysis whether administration of statins before carotid artery stenting (CAS) is associated with fewer periprocedural adverse events. aRESULTS: Eleven studies comprising 4088 patients were included. Patients who received statins prior to CAS had a significantly lower risk of stroke (OR 0.39, 95% CI 0.27 to 0.58, p<0.01; I2=0%) and death (OR 0.30, 95% CI 0.10 to 0.96, p=0.042; I2=0%). Statin use was not associated with a reduced risk of transient ischemic attack or myocardial infarction. In meta-regression analysis, other trial-level baseline characteristics had no significant influence on the association of statin treatment with death or stroke. aEnglish aIN PROCESS -- NOT YET INDEXED aMedStar Washington Hospital Center aMedicine/General Internal Medicine aJournal Article aJonnalagadda, Anil K uhttps://dx.doi.org/10.1177/1526602818794030zhttps://dx.doi.org/10.1177/1526602818794030